Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COH-MC-17 and CD4+ T-cell-depleted Haploidentical Transplant in Sickle Cell Disease
NCT03249831Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jan 2019
- Primary completion
- Jan 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD4+ T-cell-depleted haploidentical hematopoietic transplant in sickle cell disease (SCD), sponsored by City of Hope. Primary endpoints: Toxicity per NCI-Common Terminology Criteria for Adverse Events version 4.0, Unacceptable Toxicity at least possibly related to COH-MC-17 and 2 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
CD4+ T-cell-depleted haploidentical hematopoietic transplant
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03249831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249831.